Law360 (July 16, 2019, 5:04 PM EDT) -- Loestrin end payors on Monday moved for preliminary approval of their $1 million settlement with Lupin Pharmaceuticals to resolve their portion of litigation accusing the company of working with another pharmaceutical duo to sideline generic alternatives to the widely used birth control drug.
A host of end payors such as retailers, drug wholesalers, insurance companies and other drug purchasers are suing Warner Chilcott and Watson Pharmaceuticals in Rhode Island federal court for allegedly cutting a decade-old deal that drove Loestrin rivals off the market, allowing Warner Chilcott to keep demanding a premium for its brand-name contraception.
Lupin had been a part...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!